Janice Mehnert
NYU Langone Health · New York Langone Health · ECOG-ACRIN Cancer Research Group
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Janice Mehnert as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:03 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05428007 · Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV MelanomaNYU Langone Health · recruiting · Melanoma, Unresectable Melanoma · principal investigator
- Ph2NCT03999749 · A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV MelanomaNYU Langone Health · active not recruiting · Melanoma · principal investigator
- Ph3NCT03712605 · Testing Pembrolizumab Versus Observation in Patients With Merkel Cell Carcinoma After Surgery, STAMP TrialNational Cancer Institute (NCI) · active not recruiting · Pathologic Stage I Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage II Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:03 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- “Promoting a Culture Of Innovation, Mentorship, and Clinical Investigation in NCI Sponsored Clinical Research: NCI Research Specialist (Clinician Scientist) Award Application of Janice M. Mehnert, M.DR50CA282100 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · fiscal years 2023 to 2026 · $110,706 awarded in 2026Same name and institution; not confirmed by an ID
- Clinical Protocol and Data ManagementP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · fiscal years 2024 to 2026 · $391,425 awarded in 2026Same name and institution; not confirmed by an ID
- K12 Training for Clinical and Translational Oncology ResearchersK12CA270377 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · fiscal years 2025 to 2026 · $809,988 awarded in 2026Same name and institution; not confirmed by an ID
- Correlative biomarkers of IL-6 blockade combined with checkpoint inhibitionR01CA244936 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · fiscal years 2024 · $563,722 awarded in 2024Same name and institution; not confirmed by an ID
- Clinical Investigations and Precision TherapeuticsP30CA072720 · NCI · RBHS -CANCER INSTITUTE OF NEW JERSEY · fiscal years 2019 to 2020 · $29,643 awarded in 2020Same name and institution; not confirmed by an ID
- Wisconsin and New Jersey Alliance in Precision Experimental TherapeuticsUM1CA186716 · NCI · RBHS -CANCER INSTITUTE OF NEW JERSEY · fiscal years 2016 to 2018 · $500,917 awarded in 2018Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- ECOG-ACRIN Network Group Operations CenterU10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · fiscal years 2014 to 2026Named on NCT03712605
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:03 UTC. The ranking covers the 200 most relevant of 48 PubMed records, and a shared surname and initials can bring in a namesake. All 48 on PubMed
- 780 citationsRCR 26.8
- Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study.J Clin Oncol · 2017417 citationsRCR 12.0
- Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study.J Clin Oncol · 2017413 citationsRCR 12.9
- Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study.J Clin Oncol · 2017382 citationsRCR 11.9
- Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028.Gynecol Oncol · 2019236 citationsRCR 8.0
- Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer.BMC Cancer · 2019174 citationsRCR 6.9
- Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial.J Immunother Cancer · 2020154 citationsRCR 6.4
- First-in-Human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors.Clin Cancer Res · 2017145 citationsRCR 4.3
- 127 citationsRCR 5.8
- Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial.Nat Med · 202099 citationsRCR 3.1